Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	427.65	391.57	549.91	285.12	262.13	69.88
Short-Term Investments	-	-	-	231.45	-	-
Cash & Short-Term Investments	427.65	391.57	549.91	516.56	262.13	69.88
Cash Growth	10.41%	-28.79%	6.46%	97.07%	275.09%	-
Accounts Receivable	-	-	-	0.03	0.16	0.15
Other Receivables	2.26	3.09	2.75	9.06	-	-
Receivables	2.26	3.09	2.75	9.09	0.16	0.15
Restricted Cash	1.56	3.23	1.28	1.55	2	5.29
Other Current Assets	42.72	40.25	15.87	7.51	2.16	1.08
Total Current Assets	474.17	438.14	569.81	534.72	266.44	76.4
Property, Plant & Equipment	159.19	120.17	121.45	64.73	25.97	24.37
Goodwill	52.06	52.06	0.8	0.8	0.8	-
Other Intangible Assets	34.09	36.44	1.31	1.39	1.69	-
Other Long-Term Assets	6.99	6.89	7.92	8.72	3.69	0.07
Total Assets	726.5	653.7	701.29	610.35	298.59	101.43
Accounts Payable	2.26	3.95	4.59	2.82	1.07	1.26
Accrued Expenses	38.71	41.76	30.29	27.67	10.49	4.88
Current Portion of Long-Term Debt	0.07	0.04	0.1	0.09	1.07	0.08
Current Portion of Leases	16.38	6.12	5.95	-	-	-
Current Unearned Revenue	49.58	36.43	56.73	10	10	-
Other Current Liabilities	1.89	4.87	2.62	6.08	0.47	0.47
Total Current Liabilities	108.89	93.17	100.27	46.66	23.1	6.68
Long-Term Debt	1.02	1.1	0.54	0.63	11.41	12.42
Long-Term Leases	73.16	43.41	44.42	-	-	-
Long-Term Unearned Revenue	15.71	51.24	70.26	6.67	16.67	-
Long-Term Deferred Tax Liabilities	0.17	1.34	-	-	-	-
Other Long-Term Liabilities	3	-	-	13.45	5.38	5.49
Total Liabilities	201.94	190.26	215.48	67.41	56.56	24.59
Common Stock	0	0	0	0	-	-
Additional Paid-In Capital	1,777	1,431	1,125	943.14	7.31	2.33
Retained Earnings	-1,252	-967.62	-639.56	-400.08	-213.6	-126.6
Comprehensive Income & Other	-	-	-	-0.13	-	-
Total Common Equity	524.56	463.44	485.81	542.94	-206.29	-124.27
Shareholders' Equity	524.56	463.44	485.81	542.94	242.02	76.84
Total Liabilities & Equity	726.5	653.7	701.29	610.35	298.59	101.43
Total Debt	90.63	50.67	51.01	0.72	12.49	12.5
Net Cash (Debt)	337.02	340.89	498.91	515.84	249.64	57.39
Net Cash Growth	0.35%	-31.67%	-3.28%	106.63%	335.00%	-
Net Cash Per Share	1.37	1.64	2.84	4.12	11.46	2.66
Filing Date Shares Outstanding	286.84	234.65	191.23	170.77	22.31	21.64
Total Common Shares Outstanding	286.12	234.27	191.02	170.27	22.31	21.64
Working Capital	365.28	344.97	469.55	488.06	243.34	69.71
Book Value Per Share	1.83	1.98	2.54	3.19	-9.24	-5.74
Tangible Book Value	438.41	374.94	483.7	540.75	-208.78	-124.27
Tangible Book Value Per Share	1.53	1.60	2.53	3.18	-9.36	-5.74
Machinery	92.12	82.22	67.69	53.08	20.78	17.19
Construction In Progress	1.71	3.23	8.75	16.45	1.36	-
Leasehold Improvements	47.04	45.93	41.87	13.94	13.79	12.9

Source: S&P Capital IQ. Standard template. Financial Sources.